Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine
Abstract BA.4 and BA.5 (BA.4/5), the subvariants of Omicron, are more transmissible than BA.1 with more robust immune evasion capability because of its unique spike protein mutations. In light of such situation, the vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.238 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589938251530240 |
|---|---|
| author | Dandan Peng Tingmei Zhao Weiqi Hong Minyang Fu Cai He Li Chen Wenyan Ren Hong Lei Jingyun Yang Aqu Alu Yanghong Ni Jian Liu Jiong Li Wei Wang Guobo Shen Zhiwei Zhao Li Yang Jinliang Yang Zhenling Wang Yoshimasa Tanaka Guangwen Lu Xiangrong Song Xiawei Wei |
| author_facet | Dandan Peng Tingmei Zhao Weiqi Hong Minyang Fu Cai He Li Chen Wenyan Ren Hong Lei Jingyun Yang Aqu Alu Yanghong Ni Jian Liu Jiong Li Wei Wang Guobo Shen Zhiwei Zhao Li Yang Jinliang Yang Zhenling Wang Yoshimasa Tanaka Guangwen Lu Xiangrong Song Xiawei Wei |
| author_sort | Dandan Peng |
| collection | DOAJ |
| description | Abstract BA.4 and BA.5 (BA.4/5), the subvariants of Omicron, are more transmissible than BA.1 with more robust immune evasion capability because of its unique spike protein mutations. In light of such situation, the vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is in desperate need of the third booster. It has been reported that heterologous boosters might produce more effective immunity against wild‐type SARS‐CoV‐2 and the variants. Additionally, the third heterologous protein subunit booster should be considered potentially. In the present study, we prepared a Delta full‐length spike protein sequence‐based mRNA vaccine as the “priming” shot and developed a recombinant trimeric receptor‐binding domain (RBD) protein vaccine referred to as RBD–HR/trimer as a third heterologous booster. Compared to the homologous mRNA group, the heterologous group (RBD–HR/trimer vaccine primed with two mRNA vaccines) induced higher neutralizing antibody titers against BA.4/5‐included SARS‐CoV‐2 variants. In addition, heterologous vaccination exhibited stronger cellular immune response and long‐lasting memory response than the homologous mRNA vaccine. In conclusion, a third heterologous boosting with RBD–HR/trimer following two‐dose mRNA priming vaccination should be a superior strategy than a third homologous mRNA vaccine. The RBD–HR/trimer vaccine becomes an appropriate candidate for a booster immune injection. |
| format | Article |
| id | doaj-art-c5d5e2397951419799d42876e6ce0022 |
| institution | Kabale University |
| issn | 2688-2663 |
| language | English |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj-art-c5d5e2397951419799d42876e6ce00222025-01-24T05:36:29ZengWileyMedComm2688-26632023-04-0142n/an/a10.1002/mco2.238Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccineDandan Peng0Tingmei Zhao1Weiqi Hong2Minyang Fu3Cai He4Li Chen5Wenyan Ren6Hong Lei7Jingyun Yang8Aqu Alu9Yanghong Ni10Jian Liu11Jiong Li12Wei Wang13Guobo Shen14Zhiwei Zhao15Li Yang16Jinliang Yang17Zhenling Wang18Yoshimasa Tanaka19Guangwen Lu20Xiangrong Song21Xiawei Wei22Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaCenter for Medical Innovation Nagasaki University Nagasaki JapanLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital Sichuan University Chengdu ChinaAbstract BA.4 and BA.5 (BA.4/5), the subvariants of Omicron, are more transmissible than BA.1 with more robust immune evasion capability because of its unique spike protein mutations. In light of such situation, the vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is in desperate need of the third booster. It has been reported that heterologous boosters might produce more effective immunity against wild‐type SARS‐CoV‐2 and the variants. Additionally, the third heterologous protein subunit booster should be considered potentially. In the present study, we prepared a Delta full‐length spike protein sequence‐based mRNA vaccine as the “priming” shot and developed a recombinant trimeric receptor‐binding domain (RBD) protein vaccine referred to as RBD–HR/trimer as a third heterologous booster. Compared to the homologous mRNA group, the heterologous group (RBD–HR/trimer vaccine primed with two mRNA vaccines) induced higher neutralizing antibody titers against BA.4/5‐included SARS‐CoV‐2 variants. In addition, heterologous vaccination exhibited stronger cellular immune response and long‐lasting memory response than the homologous mRNA vaccine. In conclusion, a third heterologous boosting with RBD–HR/trimer following two‐dose mRNA priming vaccination should be a superior strategy than a third homologous mRNA vaccine. The RBD–HR/trimer vaccine becomes an appropriate candidate for a booster immune injection.https://doi.org/10.1002/mco2.238heterologous vaccinationmRNA vaccinerecombinant RBD vaccineSARS‐CoV‐2 |
| spellingShingle | Dandan Peng Tingmei Zhao Weiqi Hong Minyang Fu Cai He Li Chen Wenyan Ren Hong Lei Jingyun Yang Aqu Alu Yanghong Ni Jian Liu Jiong Li Wei Wang Guobo Shen Zhiwei Zhao Li Yang Jinliang Yang Zhenling Wang Yoshimasa Tanaka Guangwen Lu Xiangrong Song Xiawei Wei Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine MedComm heterologous vaccination mRNA vaccine recombinant RBD vaccine SARS‐CoV‐2 |
| title | Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine |
| title_full | Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine |
| title_fullStr | Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine |
| title_full_unstemmed | Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine |
| title_short | Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine |
| title_sort | heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against ba 4 5 included sars cov 2 variants than homologous vaccination of mrna vaccine |
| topic | heterologous vaccination mRNA vaccine recombinant RBD vaccine SARS‐CoV‐2 |
| url | https://doi.org/10.1002/mco2.238 |
| work_keys_str_mv | AT dandanpeng heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT tingmeizhao heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT weiqihong heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT minyangfu heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT caihe heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT lichen heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT wenyanren heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT honglei heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT jingyunyang heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT aqualu heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT yanghongni heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT jianliu heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT jiongli heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT weiwang heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT guoboshen heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT zhiweizhao heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT liyang heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT jinliangyang heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT zhenlingwang heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT yoshimasatanaka heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT guangwenlu heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT xiangrongsong heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine AT xiaweiwei heterologousvaccinationwithsubunitproteinvaccineinducesasuperiorneutralizingcapacityagainstba45includedsarscov2variantsthanhomologousvaccinationofmrnavaccine |